Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp > New investor
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(38)
•••
Comment by Turtle4on May 15, 2024 12:06pm
93 Views
Post# 36041288

RE:RE:RE:RE:RE:RE:RE:RE:New investor

RE:RE:RE:RE:RE:RE:RE:RE:New investor
biorun wrote: If this was a Chinese partner, I would agree.

I have made it crystal clear to them that if we were to find out after the fact that they were withholding something we should have known earlier then the wrath of God from the long term holders would be certainly something they would have to deal with. This was acknowledged and got the clear sense they were aiming to be as transparent as possible.

So at this time, I am choosing to trust what they are telling us through the news releases and updates.

By the way, did anyone pick up on recent corporate update item which said that the therapeutic license for 1067 is still available. If they could actually secure that, it means medical grade terms, not cosmetics like royalty. Just saying this is a space we should continue to monitor.

Absolutley! And we all know how incredibly good sirona is in signing new contracts in new areas!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities